US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OS Therapies

1.88

+0.00570.30%

Volume:94.50K

Turnover:176.64K

Market Cap:62.90M

PE:-2.54

High:1.92

Open:1.90

Low:1.85

Close:1.87

52wk High:7.00

52wk Low:1.12

Shares:33.53M

Float Shares:23.38M

Volume Ratio:0.58

T/O Rate:0.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.7392

EPS(LYR):-0.8795

ROE:--

ROA:-163.50%

PB:12.72

PE(LYR):-2.13

Loading ...

Overview Company News Filings

OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial

OS Therapies Approves Key Proposals at Annual Meeting

OS Therapies Inc. held annual shareholder meeting

OS Therapies Releases Investor Presentation for Stakeholders

OS Therapies Inc. Unveils Cancer Immunotherapy Advances and Pipeline Highlights

Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate

Benzinga_recent_news

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma

OS Therapies Inc Advances OST HER2 Toward Conditional EMA Approval Following Positive Regulatory Review

OS Therapies Inc. to Attend BIO-Europe Conference in Vienna

Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies

OS Therapies Files Prospectus for Stock Resale

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Prioritizes UK and US Regulatory Submissions for OST-HER2 in Osteosarcoma, Expects UK MHRA and US FDA Filings by Early 2026

Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements

OS Therapies Is Maintained at Buy by D. Boral Capital

OS Therapies Inc. Announces Completion of Last Patient Visit in OST-504 Phase 1b Prostate Cancer Clinical Trial; Results Expected Q4 2025

OS Therapies Inc. Unveils Corporate Presentation Highlighting Listeria Platform and Cancer Immunotherapy Advances

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. as FDA Advances OST-HER2 Approval Process

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OSTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OSTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","market":"US","secType":"STK","nameCN":"OS Therapies","latestPrice":1.8757,"timestamp":1761753940860,"preClose":1.87,"halted":0,"volume":94499,"delay":0,"floatShares":23381200,"shares":33532500,"eps":-0.739242,"marketStatus":"Trading","change":0.0057,"latestTime":"10-29 12:06:54 EDT","open":1.9,"high":1.916,"low":1.85,"amount":176641.3391097,"amplitude":0.035294,"askPrice":1.91,"askSize":2,"bidPrice":1.85,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.739242,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1761768000000},"marketStatusCode":2,"adr":0,"listingDate":1719460800000,"exchange":"AMEX","adjPreClose":1.87,"preHourTrading":{"tag":"盘前","latestPrice":1.88,"preClose":1.87,"latestTime":"09:26 EDT","volume":401,"amount":755.3549982999999,"timestamp":1761744366055},"postHourTrading":{"tag":"盘后","latestPrice":1.9,"preClose":1.87,"latestTime":"19:23 EDT","volume":6014,"amount":11516.939,"timestamp":1761693834810},"volumeRatio":0.575114},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OSTX\",,,,,undefined,":{"symbol":"OSTX","floatShares":23381200,"roa":"-163.50%","roe":"--","lyrEps":-0.879526,"volumeRatio":0.575114,"shares":33532500,"dividePrice":0,"high":1.916,"amplitude":0.035294,"preClose":1.87,"low":1.85,"week52Low":1.12,"pbRate":"12.72","week52High":7,"institutionHeld":0,"latestPrice":1.8757,"eps":-0.739242,"divideRate":0,"volume":94499,"delay":0,"ttmEps":-0.739242,"open":1.9,"prevYearClose":4.28,"prevWeekClose":1.89,"prevMonthClose":1.96,"prevQuarterClose":1.96,"fiveDayClose":1.83,"twentyDayClose":2,"sixtyDayClose":1.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OSTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OSTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OSTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1743652800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OSTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OSTX","date":"2025-10-28","current":-2.529618,"percent":0.726984,"low":-14.897496,"twenty":-10.047148,"median":-5.177924,"eighty":-4.425694,"high":-2.731469,"avg":-6.846844,"sd":3.172391,"marketCap":65723680},"quantilePoints":[{"date":"2024-06-14","current":-13.217965,"twenty":-13.216533,"median":-13.214385,"eighty":-13.212238,"marketCap":102988885},{"date":"2024-06-21","current":-10.574372,"twenty":-13.217965,"median":-13.214385,"eighty":-12.156232,"marketCap":82391108},{"date":"2024-06-28","current":-13.217965,"twenty":-13.217965,"median":-13.217965,"eighty":-13.210806,"marketCap":102988885},{"date":"2024-08-02","current":-6.458845,"twenty":-13.217965,"median":-13.217965,"eighty":-11.101659,"marketCap":50324634},{"date":"2024-08-09","current":-8.117559,"twenty":-13.217965,"median":-10.433676,"eighty":-8.215548,"marketCap":63248641},{"date":"2024-08-16","current":-10.993719,"twenty":-13.216533,"median":-10.29298,"eighty":-8.15204,"marketCap":70975778},{"date":"2024-08-23","current":-13.004275,"twenty":-13.182439,"median":-10.833368,"eighty":-8.309008,"marketCap":83955991},{"date":"2024-08-30","current":-11.710317,"twenty":-13.188909,"median":-11.710317,"eighty":-8.610078,"marketCap":75602161},{"date":"2024-09-06","current":-12.939577,"twenty":-13.217965,"median":-12.391225,"eighty":-8.620371,"marketCap":83538300},{"date":"2024-09-13","current":-11.32213,"twenty":-13.217965,"median":-12.261039,"eighty":-9.289415,"marketCap":73096012},{"date":"2024-09-20","current":-11.483875,"twenty":-13.217965,"median":-11.710317,"eighty":-10.29298,"marketCap":74140241},{"date":"2024-09-27","current":-9.575287,"twenty":-13.210806,"median":-11.435351,"eighty":-9.575287,"marketCap":61818342},{"date":"2024-10-04","current":-9.727327,"twenty":-13.101322,"median":-11.354479,"eighty":-9.316172,"marketCap":62799917},{"date":"2024-10-11","current":-9.931126,"twenty":-13.068973,"median":-11.192735,"eighty":-9.413543,"marketCap":64115645},{"date":"2024-10-18","current":-9.769381,"twenty":-13.068973,"median":-10.859351,"eighty":-9.542938,"marketCap":63071416},{"date":"2024-10-25","current":-9.413543,"twenty":-13.004275,"median":-10.610453,"eighty":-9.542938,"marketCap":60774113},{"date":"2024-10-31","current":-8.782738,"twenty":-12.952517,"median":-10.592413,"eighty":-9.394069,"marketCap":56701621},{"date":"2024-11-08","current":-9.085848,"twenty":-12.836061,"median":-10.29298,"eighty":-9.218608,"marketCap":58658505},{"date":"2024-11-15","current":-7.116768,"twenty":-12.603148,"median":-10.141393,"eighty":-8.950952,"marketCap":45946065},{"date":"2024-11-22","current":-5.272053,"twenty":-12.423258,"median":-9.769381,"eighty":-8.605027,"marketCap":38782655},{"date":"2024-11-29","current":-6.178419,"twenty":-12.235002,"median":-9.759676,"eighty":-8.507772,"marketCap":45450128},{"date":"2024-12-06","current":-5.370028,"twenty":-11.917351,"median":-9.716005,"eighty":-8.143742,"marketCap":39503383},{"date":"2024-12-13","current":-12.876517,"twenty":-11.917351,"median":-9.704683,"eighty":-7.804035,"marketCap":94723165},{"date":"2024-12-20","current":-11.288606,"twenty":-11.937313,"median":-9.73218,"eighty":-8.125896,"marketCap":83042057},{"date":"2024-12-27","current":-14.738704,"twenty":-12.001827,"median":-9.761941,"eighty":-8.139646,"marketCap":108421919},{"date":"2025-01-03","current":-12.068126,"twenty":-12.384347,"median":-9.850254,"eighty":-8.168424,"marketCap":88776420},{"date":"2025-01-10","current":-14.782011,"twenty":-12.810182,"median":-10.086184,"eighty":-8.234384,"marketCap":108740495},{"date":"2025-01-17","current":-11.8949,"twenty":-12.876517,"median":-10.189917,"eighty":-8.475423,"marketCap":87502117},{"date":"2025-01-24","current":-8.430366,"twenty":-12.823449,"median":-10.125219,"eighty":-8.466412,"marketCap":62016063},{"date":"2025-01-31","current":-5.629868,"twenty":-12.632281,"median":-9.850254,"eighty":-8.128675,"marketCap":41414837},{"date":"2025-02-07","current":-5.600996,"twenty":-12.558673,"median":-9.759676,"eighty":-7.471942,"marketCap":41202453},{"date":"2025-02-14","current":-5.745352,"twenty":-12.423258,"median":-9.716005,"eighty":-6.985183,"marketCap":42264372},{"date":"2025-02-21","current":-5.456641,"twenty":-12.370592,"median":-9.688508,"eighty":-6.36129,"marketCap":40140534},{"date":"2025-02-28","current":-4.734863,"twenty":-12.322192,"median":-9.575287,"eighty":-6.039722,"marketCap":34830939},{"date":"2025-03-07","current":-4.850347,"twenty":-12.19815,"median":-9.413543,"eighty":-5.818713,"marketCap":35680475},{"date":"2025-03-14","current":-4.619378,"twenty":-12.093217,"median":-9.316172,"eighty":-5.658739,"marketCap":33981404},{"date":"2025-03-21","current":-4.590507,"twenty":-12.033481,"median":-9.267973,"eighty":-5.589448,"marketCap":33769021},{"date":"2025-03-28","current":-4.677121,"twenty":-11.941094,"median":-9.085848,"eighty":-5.445093,"marketCap":34406172},{"date":"2025-04-04","current":-3.682014,"twenty":-11.842932,"median":-9.000397,"eighty":-5.346931,"marketCap":32707102},{"date":"2025-04-11","current":-2.731469,"twenty":-11.788323,"median":-8.747948,"eighty":-5.012916,"marketCap":24263468},{"date":"2025-04-17","current":-3.828934,"twenty":-11.749136,"median":-8.669517,"eighty":-4.901959,"marketCap":34012183},{"date":"2025-04-25","current":-3.926486,"twenty":-11.61974,"median":-8.601309,"eighty":-4.833024,"marketCap":34878735},{"date":"2025-05-02","current":-4.706906,"twenty":-11.475058,"median":-8.516979,"eighty":-4.792605,"marketCap":41811155},{"date":"2025-05-09","current":-4.804459,"twenty":-11.45771,"median":-8.491597,"eighty":-4.792605,"marketCap":42677707},{"date":"2025-05-16","current":-4.048427,"twenty":-11.438586,"median":-8.234384,"eighty":-4.718089,"marketCap":35961926},{"date":"2025-05-23","current":-2.933033,"twenty":-11.406237,"median":-8.124506,"eighty":-4.677121,"marketCap":33145630},{"date":"2025-05-30","current":-3.928425,"twenty":-11.380358,"median":-7.63641,"eighty":-4.64825,"marketCap":44394361},{"date":"2025-06-06","current":-4.052742,"twenty":-11.348009,"median":-7.333748,"eighty":-4.596281,"marketCap":45799246},{"date":"2025-06-13","current":-4.574874,"twenty":-11.315425,"median":-7.167274,"eighty":-4.590507,"marketCap":51699762},{"date":"2025-06-20","current":-4.525147,"twenty":-11.288606,"median":-6.448552,"eighty":-4.525147,"marketCap":51137808},{"date":"2025-06-27","current":-4.500284,"twenty":-11.257432,"median":-6.245836,"eighty":-4.450557,"marketCap":50856831},{"date":"2025-07-03","current":-4.804944,"twenty":-11.153916,"median":-6.178419,"eighty":-4.480042,"marketCap":54299732},{"date":"2025-07-11","current":-4.384839,"twenty":-11.071717,"median":-6.001438,"eighty":-4.444649,"marketCap":49552214},{"date":"2025-07-18","current":-4.411096,"twenty":-11.057637,"median":-5.848373,"eighty":-4.413618,"marketCap":49848934},{"date":"2025-07-25","current":-5.118748,"twenty":-11.006503,"median":-5.726085,"eighty":-4.413618,"marketCap":57845975},{"date":"2025-08-01","current":-5.266689,"twenty":-10.886225,"median":-5.658739,"eighty":-4.423405,"marketCap":59517824},{"date":"2025-08-08","current":-5.177924,"twenty":-10.817778,"median":-5.632611,"eighty":-4.43502,"marketCap":58514715},{"date":"2025-08-15","current":-6.36145,"twenty":-10.649839,"median":-5.600996,"eighty":-4.43838,"marketCap":71889507},{"date":"2025-08-22","current":-5.360009,"twenty":-10.610453,"median":-5.567348,"eighty":-4.444649,"marketCap":76540639},{"date":"2025-08-29","current":-5.047341,"twenty":-10.610453,"median":-5.538676,"eighty":-4.449676,"marketCap":72075768},{"date":"2025-09-05","current":-4.667674,"twenty":-10.601601,"median":-5.456641,"eighty":-4.458388,"marketCap":66654139},{"date":"2025-09-12","current":-5.119065,"twenty":-10.582903,"median":-5.4212,"eighty":-4.477891,"marketCap":73099984},{"date":"2025-09-19","current":-4.897461,"twenty":-10.460155,"median":-5.370028,"eighty":-4.495136,"marketCap":69935483},{"date":"2025-09-26","current":-4.675856,"twenty":-10.329392,"median":-5.362697,"eighty":-4.515202,"marketCap":66770981},{"date":"2025-10-03","current":-4.409931,"twenty":-10.231142,"median":-5.325865,"eighty":-4.459866,"marketCap":62973579},{"date":"2025-10-10","current":-4.520733,"twenty":-10.170508,"median":-5.292169,"eighty":-4.471291,"marketCap":64555830},{"date":"2025-10-17","current":-4.099684,"twenty":-10.138159,"median":-5.266689,"eighty":-4.443146,"marketCap":58543277},{"date":"2025-10-24","current":-4.250282,"twenty":-10.078376,"median":-5.177924,"eighty":-4.421116,"marketCap":60693806},{"date":"2025-10-28","current":-4.602516,"twenty":-10.047148,"median":-5.177924,"eighty":-4.425694,"marketCap":65723680}],"updateTime":1761734403421},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OSTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2577367291","title":"OS Therapies Reports Positive Survival Data from Phase 2b OST-HER2 Osteosarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2577367291","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577367291?lang=en_us&edition=fundamental","pubTime":"2025-10-22 21:16","pubTimestamp":1761138969,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced additional overall and event free survival data from its 41-patient Phase 2b clinical trial of OST-HER2, an off-the-shelf immunotherapeutic candidate for recurrent, fully resected, pulmonary metastatic osteosarcoma. The company previously presented statistically significant positive final 2-year overall survival data from this trial on October 10, 2025. Subgroup analyses were performed following participation in an FDA/Osteosarcoma Institute workshop. The 1-year event free survival was reported as 28.6% among evaluable patients. OS Therapies plans to meet with regulatory agencies, including the FDA, MHRA, and EMA, to review the survival data and discuss plans to file for Biologics License Authorization under the FDA's Accelerated Approval Program and for conditional approvals in the UK and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL472r3y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2577180775","title":"OS Therapies Approves Key Proposals at Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577180775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577180775?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:56","pubTimestamp":1761080163,"startTime":"0","endTime":"0","summary":"An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On October 21, 2025, OS Therapies Incorporated held its annual meeting...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-approves-key-proposals-at-annual-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","OSTX","BK4139","OS"],"gpt_icon":0},{"id":"2577680447","title":"OS Therapies Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577680447","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577680447?lang=en_us&edition=fundamental","pubTime":"2025-10-22 04:16","pubTimestamp":1761077818,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. held its annual meeting of stockholders on October 21, 2025. Stockholders elected Paul A. Romness, John Ciccio, Avril McKean Dieser, Karim Galzahr, Olivier R. Jarry, and Theodore F. Search to the board of directors. Approval was granted for the issuance of shares of common stock to Ayala Pharmaceuticals, Inc. in connection with an asset purchase transaction. Stockholders also approved an amendment to increase the number of authorized shares of common stock from 50 million to 150 million. An amendment to the company's incentive compensation plan was approved, increasing the number of shares available for issuance under the plan and the maximum number of shares that may be granted to an individual as performance-based compensation. A resolution approving a shareholder rights agreement and authorizing the board of directors to implement it when deemed appropriate was adopted. Additionally, the appointment of MaloneBailey, LLP as independent registered public accounting f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nNDL3vp3V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADXS","OSTX","BK4139"],"gpt_icon":0},{"id":"2576062943","title":"OS Therapies Releases Investor Presentation for Stakeholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2576062943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576062943?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:28","pubTimestamp":1760736509,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On October 17, 2025, OS Therapies Incorporated announced the posting of an inv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-releases-investor-presentation-for-stakeholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-releases-investor-presentation-for-stakeholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","OS","BK4097","BK4139"],"gpt_icon":0},{"id":"2576063323","title":"OS Therapies Inc. Unveils Cancer Immunotherapy Advances and Pipeline Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2576063323","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576063323?lang=en_us&edition=fundamental","pubTime":"2025-10-18 02:14","pubTimestamp":1760724872,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has released a corporate presentation highlighting its recent developments and pipeline progress. The company has acquired all listeria-based assets from Advaxis/Ayala, with over $300 million invested in the listeria platform to date. Its lead clinical program, OST-HER2, targets osteosarcoma with additional applications in breast cancer and other solid tumors. The total addressable market for these assets and follow-on applications is estimated at $258 billion. OST-HER2 has received orphan drug, fast track, and rare pediatric disease designations from the FDA, and the company is preparing for meetings with global regulatory agencies regarding submissions for human osteosarcoma. Accelerated approval is targeted for 2026, and a Priority Review Voucher could be issued upon approval, with recent comparable sales valued at $160 million. Other pipeline highlights include a next-generation tunable drug conjugate  and ongoing clinical and preclinical programs in multiple canc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDLb9DPvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX","ADXS"],"gpt_icon":0},{"id":"2574102442","title":"Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2","url":"https://stock-news.laohu8.com/highlight/detail?id=2574102442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574102442?lang=en_us&edition=fundamental","pubTime":"2025-10-11 03:45","pubTimestamp":1760125523,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated, retaining the price target of $6.00. Jason McCarthy has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-regulatory-progress-and-market-potential-justify-buy-rating-for-os-therapies-ost-her2-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-regulatory-progress-and-market-potential-justify-buy-rating-for-os-therapies-ost-her2-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OST","PRGS","OSTX"],"gpt_icon":0},{"id":"2574170377","title":"OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2574170377","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574170377?lang=en_us&edition=fundamental","pubTime":"2025-10-10 22:40","pubTimestamp":1760107200,"startTime":"0","endTime":"0","summary":"OS Therapies reports 75% two-year survival in osteosarcoma trial, plans regulatory filings with the FDA, EMA, and MHRA following positive Phase 2b results.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/10/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/10/biotech-lab.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48149412/os-therapies-reports-strong-2-year-survival-data-for-bone-cancer-immunotherapy-candidate","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48149412/os-therapies-reports-strong-2-year-survival-data-for-bone-cancer-immunotherapy-candidate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4097","IE00BZ1G4Q59.USD","IE00BFXG1179.USD","LU2237443622.USD","OS","LU0971096721.USD","IE00BKVL7J92.USD","OSTX","LU2237443382.USD","CMC","LU2237443465.HKD","BK4006","LU0149725797.USD","LU2237443549.SGD","LU0267386448.USD","LU2237443978.SGD","LU0882574139.USD","BK4139","LU0170899867.USD","LU2746668461.USD","IE00B1BXHZ80.USD","IE00BHPRN162.USD","LU2746668974.SGD","LU1363072403.SGD","LU2237443895.HKD"],"gpt_icon":0},{"id":"2574176037","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2574176037","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574176037?lang=en_us&edition=fundamental","pubTime":"2025-10-10 20:45","pubTimestamp":1760100300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 10, 2025 08:45 ET (12:45 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2574112473","title":"OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2574112473","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574112473?lang=en_us&edition=fundamental","pubTime":"2025-10-10 18:01","pubTimestamp":1760090468,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. announced statistically significant positive final 2-year overall survival data from its Phase 2b trial of OST-HER2, an off-the-shelf immunotherapy candidate for the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma. The results showed that 75% of OST-HER2 treated patients  achieved 2-year overall survival, compared with 40% in historical controls . Subgroup analysis indicated that 100% of patients who achieved 12-month Event Free Survival  reached 2-year overall survival, while 59% of those who did not achieve EFS reached 2-year overall survival. OS Therapies plans to present further data and discuss the regulatory pathway during an investor conference call scheduled for October 13, 2025. Additional prospective biomarker analyses are expected to be completed by November 2025, ahead of planned regulatory submissions in the UK, US, and EU.Disclaimer: This news brief was created by Public Technologies  using generative artificial intell","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL5jKSG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OS Therapies announces positive Phase 2b trial results for OSTHER2 in metastatic osteosarcoma","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2574964151","title":"OS Therapies Inc Advances OST HER2 Toward Conditional EMA Approval Following Positive Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2574964151","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574964151?lang=en_us&edition=fundamental","pubTime":"2025-10-09 19:40","pubTimestamp":1760010057,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has announced a positive regulatory update following a meeting with the European Medicines Agency  rapporteur, the Dutch Medicines Evaluation Board. The discussions confirmed alignment on key safety, non-clinical, and manufacturing data for the company's OST-HER2 immunotherapy, currently in a Phase 2b trial for recurrent, fully-resected, pulmonary metastatic osteosarcoma. The EMA rapporteur acknowledged overall survival as a key efficacy endpoint and indicated that positive two-year survival data could support a conditional marketing authorization. Additionally, OS Therapies recently began the Marketing Authorisation Application process with the UK MHRA, which granted the company an expedited Market Access Scientific Advice Meeting to accelerate patient access. The regulatory pathway also includes plans for a post-market confirmatory trial that may expand the use of OST-HER2 to other osteosarcoma settings. No new grant or funding announcement involving OS Therapies In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL3qDkm2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2573961837","title":"OS Therapies Inc. to Attend BIO-Europe Conference in Vienna","url":"https://stock-news.laohu8.com/highlight/detail?id=2573961837","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573961837?lang=en_us&edition=fundamental","pubTime":"2025-10-07 23:50","pubTimestamp":1759852241,"startTime":"0","endTime":"0","summary":"OS Therapies Inc., a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, will participate in the Cell and Gene Meeting on the Mesa from October 6-8, 2025, at the Arizona Biltmore in Phoenix, AZ. The company will engage in partnering and one-on-one meetings, represented by Chairman & CEO Paul Romness.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on October 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL8GMp9q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2572371155","title":"Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2572371155","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572371155?lang=en_us&edition=fundamental","pubTime":"2025-10-01 22:15","pubTimestamp":1759328117,"startTime":"0","endTime":"0","summary":"OS Therapies Incorporated, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-regulatory-advances-and-promising-clinical-data-drive-buy-rating-for-os-therapies-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-regulatory-advances-and-promising-clinical-data-drive-buy-rating-for-os-therapies-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"gpt_icon":0},{"id":"2572374136","title":"OS Therapies Files Prospectus for Stock Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2572374136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572374136?lang=en_us&edition=fundamental","pubTime":"2025-10-01 04:31","pubTimestamp":1759264286,"startTime":"0","endTime":"0","summary":"The latest announcement is out from OS Therapies Incorporated ( ($OSTX) ). On September 30, 2025, OS Therapies Incorporated filed a prospectus supp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-for-stock-resale?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/os-therapies-files-prospectus-for-stock-resale?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX","BK4097","OS","BK4139"],"gpt_icon":0},{"id":"2571328118","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2571328118","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571328118?lang=en_us&edition=fundamental","pubTime":"2025-09-30 21:05","pubTimestamp":1759237500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2025 09:05 ET (13:05 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2571834490","title":"OS Therapies Inc. Prioritizes UK and US Regulatory Submissions for OST-HER2 in Osteosarcoma, Expects UK MHRA and US FDA Filings by Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2571834490","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571834490?lang=en_us&edition=fundamental","pubTime":"2025-09-30 19:40","pubTimestamp":1759232454,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Prioritizes UK and US Regulatory Submissions for OST-HER2 in Osteosarcoma, Expects UK MHRA and US FDA Filings by Early 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on September 30, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL8cNNYg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0},{"id":"2568448461","title":"Optimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2568448461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568448461?lang=en_us&edition=fundamental","pubTime":"2025-09-17 00:15","pubTimestamp":1758039317,"startTime":"0","endTime":"0","summary":"Analyst Jason McCarthy of Maxim Group maintained a Buy rating on OS Therapies Incorporated, retaining the price target of $6.00. Jason McCarthy has...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-on-os-therapies-inc-amid-promising-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-on-os-therapies-inc-amid-promising-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OSTX"],"gpt_icon":0},{"id":"2566908693","title":"OS Therapies Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2566908693","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566908693?lang=en_us&edition=fundamental","pubTime":"2025-09-12 23:32","pubTimestamp":1757691120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OSTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 12, 2025 11:32 ET (15:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX"],"gpt_icon":0},{"id":"2566976130","title":"OS Therapies Inc. Announces Completion of Last Patient Visit in OST-504 Phase 1b Prostate Cancer Clinical Trial; Results Expected Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2566976130","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566976130?lang=en_us&edition=fundamental","pubTime":"2025-09-12 19:40","pubTimestamp":1757677259,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. Announces Completion of Last Patient Visit in OST-504 Phase 1b Prostate Cancer Clinical Trial; Results Expected Q4 2025. OS Therapies Inc., a clinical-stage biotechnology company specializing in cancer immunotherapy and antibody drug conjugates, announced the completion of patient visits for their OST-504 Phase 1b clinical trial. The trial, which involved seven patients with biochemically recurrent prostate cancer, has concluded all patient interactions, and the company plans to release the clinical data in the fourth quarter of 2025. Additionally, OS Therapies will present updated two-year overall survival data from its Phase 2b clinical trial of OST-HER2, focused on preventing recurrent pulmonary metastatic osteosarcoma, on October 10, 2025. These developments are part of the company's ongoing efforts to address significant unmet medical needs in cancer treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL8pT7yv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2566393315","title":"OS Therapies Inc. Unveils Corporate Presentation Highlighting Listeria Platform and Cancer Immunotherapy Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2566393315","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566393315?lang=en_us&edition=fundamental","pubTime":"2025-09-11 07:27","pubTimestamp":1757546828,"startTime":"0","endTime":"0","summary":"OS Therapies Inc. has released a corporate presentation detailing their advancements and investment highlights. Over $300 million has been invested in their listeria platform, with a focus on the OST-HER2 program targeting osteosarcoma and other solid tumor cancers. The total addressable market for these assets and applications is estimated at $258 billion. The presentation also outlines their OST-tADC platform, featuring a unique patented silicone linker aimed at improving safety and efficacy. The company's clinical-stage pipeline includes programs in osteosarcoma, HPV cancers, non-small cell lung cancer, glioblastoma, breast cancer, and prostate cancer, with positive Phase 2b data in some areas. OS Therapies is targeting accelerated approval for certain programs in late 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and ti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL7JPBjL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSTX","BK4139"],"gpt_icon":0},{"id":"2566463710","title":"Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. as FDA Advances OST-HER2 Approval Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2566463710","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566463710?lang=en_us&edition=fundamental","pubTime":"2025-09-09 05:13","pubTimestamp":1757366016,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via Newsfile  on September 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL1sjWdd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OSTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}